Search

Your search keyword '"Walker, Randall C"' showing total 175 results
Start Over Author "Walker, Randall C"
175 results on '"Walker, Randall C"'

4. Reply to Davido et al

Author

Khanna, Sahil, Tariq, Raseen, Tosh, Pritish K., Walker, Randall C., Razonable, Raymund R., and Pardi, Darrell S.

Published
2018

6. Histoplasmosis Complicating Tumor Necrosis Factor–α Blocker Therapy: A Retrospective Analysis of 98 Cases

Author

Vergidis, Paschalis, Avery, Robin K., Wheat, L. Joseph, Dotson, Jennifer L., Assi, Maha A., Antoun, Smyrna A., Hamoud, Kassem A., Burdette, Steven D., Freifeld, Alison G., McKinsey, David S., Money, Mary E., Myint, Thein, Andes, David R., Hoey, Cynthia A., Kaul, Daniel A., Dickter, Jana K., Liebers, David E., Miller, Rachel A., Muth, William E., Prakash, Vidhya, Steiner, Frederick T., Walker, Randall C., and Hage, Chadi A.

Published
2015

9. Clinicopathologic Characteristics, Treatment, and Outcomes of Post-transplant Lymphoproliferative Disorders: A Single-institution Experience Using 2017 WHO Diagnostic Criteria

Author

King, Rebecca L., primary, Khurana, Arushi, additional, Mwangi, Raphael, additional, Fama, Angelo, additional, Ristow, Kay M., additional, Maurer, Matthew J., additional, Macon, William R., additional, Ansell, Stephen M., additional, Bennani, N. Nora, additional, Kudva, Yogish C., additional, Walker, Randall C., additional, Watt, Kymberly D., additional, Schwab, Thomas R., additional, Kushwaha, Sudhir S., additional, Cerhan, James R., additional, and Habermann, Thomas M., additional

Published
2021
Full Text
View/download PDF

11. Stability in the cumulative incidence, severity and mortality of 101 cases of invasive mucormycosis in high-risk patients from 1995 to 2011: a comparison of eras immediately before and after the availability of voriconazole and echinocandin-amphotericin combination therapies

Author

Abidi, Maheen Z., Sohail, Muhammad R., Cummins, Nathan, Wilhelm, Mark, Wengenack, Nancy, Brumble, Lisa, Shah, Harshal, Jane Hata, Donna, McCullough, Ann, Wendel, Amy, Vikram, Holenarasipur R., Kusne, Shimon, Litzow, Mark, Letendre, Louis, Lahr, Brian D., Poeschla, Eric, and Walker, Randall C.

Published
2014
Full Text
View/download PDF

15. Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents

Author

Miller, Matthew A, primary, Molina, Kyle C, additional, Gutman, Jonathan A, additional, Scherger, Sias, additional, Lum, Jessica M, additional, Mossad, Sherif B, additional, Burgess, Mary, additional, Cheng, Matthew P, additional, Chuang, Sally T, additional, Jacobs, Samantha E, additional, Melendez, Dante P, additional, Shah, Dimpy P, additional, Zimmer, Andrea, additional, Sohail, M Rizwan, additional, Syed, Sadia, additional, Walker, Randall C, additional, Poeschla, Eric M, additional, and Abidi, Maheen Z, additional

Published
2020
Full Text
View/download PDF

26. Clinical Characteristics and Outcomes of an Analysis of a Single Institution Experience of the 2017 World Health Organization (WHO) Classification of Post-Transplant Lymphoproliferative Disorders (PTLD)

Author

Habermann, Thomas M., primary, Fama, Angelo, additional, Ristow, Kay M., additional, Maurer, Matthew J., additional, Macon, William R., additional, Ansell, Stephen M., additional, Bennani, Nabila Nora, additional, Kudva, Yogish C, additional, Walker, Randall C., additional, Watt, Kimberly D., additional, Schwab, Thomas R., additional, Cerhan, James R., additional, and King, Rebecca L, additional

Published
2018
Full Text
View/download PDF

27. Epstein-Barr Virus Status in Diffuse Large B Cell Lymphoma Post-Transplant Lymphoproliferative Disorder

Author

Fama, Angelo, primary, King, Rebecca L, additional, Maurer, Matthew J., additional, Ristow, Kay M., additional, Macon, William R, additional, Ansell, Stephen M, additional, Bennani, Nora N, additional, Walker, Randall C., additional, Kudva, Yogish C, additional, Watt, Kymberly D, additional, Schwab, Thomas R., additional, Cerhan, James R., additional, Nowakowski, Grzegorz S., additional, and Habermann, Thomas M., additional

Published
2018
Full Text
View/download PDF

30. Mucormycosis in Hematopoietic Cell Transplant Recipients and in Patients With Hematological Malignancies in the Era of New Antifungal Agents.

Author

Miller, Matthew A, Molina, Kyle C, Gutman, Jonathan A, Scherger, Sias, Lum, Jessica M, Mossad, Sherif B, Burgess, Mary, Cheng, Matthew P, Chuang, Sally T, Jacobs, Samantha E, Melendez, Dante P, Shah, Dimpy P, Zimmer, Andrea, Sohail, M Rizwan, Syed, Sadia, Walker, Randall C, Poeschla, Eric M, and Abidi, Maheen Z

Subjects
ANTIFUNGAL agents, MUCORMYCOSIS, TRANSPLANTATION of organs, tissues, etc., AMPHOTERICIN B
Abstract

Background The survival benefit of combination antifungal therapy for invasive mucormycosis (IM) in patients with hematologic malignancy (HM) and hematopoietic cell transplant (HCT) is not well defined. Methods This multicenter, retrospective study included HM and HCT recipients with proven or probable IM between January 1, 2007 and December 31, 2017 from 10 transplant centers across North America. Results Sixty-four patients with proven (n = 47) or probable (n = 17) IM defined by 2008 European Organization for Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) consensus definitions were included. Thirty-nine (61%) were HCT recipients (95% allogeneic). Sites of infection included rhino-orbital-cerebral (33), pulmonary (30%), disseminated (19%), gastrointestinal (3%), and cutaneous (3%). Surgical debridement was performed in 66%. Initial antifungal treatment consisted of the following: lipid formulation of amphotericin B (AmB) alone (44%), AmB + posaconazole (25%), AmB + echinocandin (13%), AmB + isavuconazole (8%), posaconazole alone (5%), and isavuconazole alone (3%). All-cause mortality at 30 days and 1 year were 38% and 66%, respectively. Initial treatment with AmB plus posaconazole or isavuconazole (n = 28) was associated with a trend toward lower treatment failure compared with AmB (n = 21) (42% vs 64%, P  = .136). Conclusions Long-term survival with IM among HM and HCT populations remains poor. However, initial use of AmB + azole in conjunction with surgery may result in less treatment failure. More evidence from prospective controlled studies is needed to confirm this observation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

32. Reply to Davido et al

Author

Khanna, Sahil, primary, Tariq, Raseen, additional, Tosh, Pritish K, additional, Walker, Randall C, additional, Razonable, Raymund R, additional, and Pardi, Darrell S, additional

Published
2017
Full Text
View/download PDF

33. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt

Author

Anaissie, Elias J., Segal, Brahm H., Graybill, John R., Arndt, Carola, Perfect, John R., Kleinberg, Michael, Pappas, Peter, Benjamin, Danny, Rubin, Robert, Aberg, Judith A., Adderson, Elisabeth E., Adler-Shohet, Felice C., Akan, Hamdi, Akova, Murat, Almyroudis, Nikolaos G., Alexander, Barbara D., Andes, David, Arrieta, Antonio, Baddley, John W., Barron, Michelle A., Belzberg, Howard, Boucher, Helen W., Boyce, Thomas G., Casadevall, Arturo, Chandrasekar, P.H., Cleary, John D., Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Daly, Jennifer S., Daoura, Nicholas, Denning, David W., dePauw, Ben, Repentigny, Louis de, Dignani, Maria Cecilia, Dismukes, William E., Donnelly, J. Peter, Donowitz, Gerald R., Dupont, Bertrand, Drusano, George, Ellis, Michael, Espinel-Ingroff, Ana, Fishman, Jay A., Fleming, Rhonda, Forrest, Graeme, Ghannoum, Mahmoud, Goldman, Mitchell, Grazziutti, Monica, Greene, John N., Greenberg, Richard N., Gubbins, Paul O., Hadley, Susan, Herbrecht, Raoul, Hiemenz, John W., Hope, William, Hospenthal, Durane R., Husain, Shahid, Ito, James I., Jacobson, Robert M., Johnson, Melissa, Keating, Michael R., Kett, Daniel H., Knapp, Katherine, Kontoyiannis, Dimitrios P., Krcmery, Vladimir C., Larsen, Robert, Laverdiere, Michel, Ljungman, Per, Lortholary, O., Maertens, Johan, Marriott, Debbie, Mattiuzzi, Gloria, McGinnis, Michael R., Morris, Michele, Nucci, Marcio, Odds, Frank C., Pankey, George A., Patterson, Thomas, Pfaller, Mike, Razonable, Raymond R., Reboli, Annette C., Rinaldi, Michael G., Roberts, Glenn D., Tudela, Juan Luis Rodriguez, Rotstein, Coleman, Ruhnke, Markus, Schuster, Mindy, Shoham, Shmuel, Sia, Irene G., Siebel, Nita, Silviera, Fernanda, Singh, Nina, Sobel, Jack, Solomkin, Joseph S., Sorrell, Tania C., Steinbach, William J., Temesgen, Zelalem, Tortorano, AnnaMaria, Vartivarian, Shahe, VerWeij, Paul, Viscoli, Claudio, Viviani, Maria Anna, Walker, Randall C., Wheat, Joseph L., Wiley, Joseph, Williamson, Peter, Wingard, John R., Yu, Victor L., and Zaoutis, Theoklis

Subjects
Clinical trials -- Evaluation, Journalism, Medical -- Evaluation, Health, Health care industry
Published
2006

35. Mucormycosis in Patients with Inflammatory Bowel Disease: Case Series and Review of the Literature

Author

Abidi, Maheen Z., Coelho-Prabhu, Nayantara, Hargreaves, James, Weiland, Tim, Van Dyken, Irminne, Tande, Aaron, Tosh, Pritish K., Walker, Randall C., and Cummins, Nathan W.

Subjects
Article Subject
Abstract

Mucormycosis is a rare and often fatal invasive fungal infection mostly seen in immune-compromised individuals. A high index of clinical suspicion is necessary, so that effective preemptive therapy can be started, as timely intervention is crucial. In this series we present three cases of invasive mucormycosis in patients with underlying inflammatory bowel disease that had received therapy with immunomodulators prior to the infection. All three had varied clinical manifestations. We also review the literature of invasive mucormycosis in patients with inflammatory bowel disease.

Published
2014
Full Text
View/download PDF

37. Transmission of Invasive Aspergillosis From a Subclinically Infected Donor to Three Different Organ Transplant Recipients

Author

Michael R. Keating, Richard C. Daly, Walker Randall C, Scott F. Davies, and Marco A. Guerrero

Subjects
Adult, Male, Pulmonary and Respiratory Medicine, medicine.medical_specialty, medicine.medical_treatment, Opportunistic Infections, Liver transplantation, Critical Care and Intensive Care Medicine, Aspergillosis, Organ transplantation, Aspergillus fumigatus, medicine, Dermatomycoses, Humans, Transplantation, Homologous, Organ donation, Heart transplantation, Endocarditis, biology, business.industry, Middle Aged, Eye infection, biology.organism_classification, medicine.disease, Kidney Transplantation, Abscess, Tissue Donors, Surgery, Transplantation, Heart Transplantation, Female, Kidney Diseases, Cardiology and Cardiovascular Medicine, business, Eye Infections, Fungal
Abstract

Objective To describe a cluster of donor-transmitted cases of invasive aspergillosis. Design Case series of epidemiologically linked eases of invasive aspergillosis. Setting Two tertiary care centers with solid-organ transplant programs. Patients Two kidney recipients, one heart recipient, and the single donor. Measurements Routine clinical, microbiological, and pathologic investigation as dictated for patient care. Epidemiologic analysis to establish linkage among cases. Results Three allografts (two kidneys and a heart) from a single donor transmitted invasive aspergillosis to the recipients. Three weeks after transplantation, the two kidney recipients had fever and urine cultures positive for Aspergillus fumigatus . The infected kidneys had multiple Aspergillus abscesses and had to be removed to cure the patients. The heart recipient had a negative workup when a diagnosis of aspergillosis was made for the kidney recipients but presented three months later with aspergillus endocarditis with hematogenous spread to the eyes and to the skin. Treatment included eye surgery, aortic valve replacement, and antifungal therapy; control of infection ensued. The donor was intensely immunosuppressed (17 days post-liver transplantation with death from intracerebral bleeding) but had no clinical or autopsy evidence of aspergillosis. Donor tracheal secretions obtained at the time of organ harvest later grew A fumigatus . Conclusion Expanded criteria for organ donation have to be balanced against infectious risk to organ recipients. A fumigatus can be transmitted from a subclinically infected donor to solid-organ transplant recipients.

Published
1996

39. Mycobacterium arupense Flexor Tenosynovitis: Case Report and Review of Antimicrobial Susceptibility Profiles for 40 Clinical Isolates

Author

Beam, Elena, primary, Vasoo, Shawn, additional, Simner, Patricia J., additional, Rizzo, Marco, additional, Mason, Erin L., additional, Walker, Randall C., additional, Deml, Sharon M., additional, Brown-Elliott, Barbara A., additional, Wallace, Richard J., additional, Wengenack, Nancy L., additional, and Sia, Irene G., additional

Published
2014
Full Text
View/download PDF

42. Epidemiology of Infections Requiring Hospitalization During Long-Term Follow-Up of Pancreas Transplantation

Author

Rostambeigi, Nassir, primary, Kudva, Yogish C., additional, John, Seby, additional, Mailankody, Sham, additional, Pedersen, Rachel A., additional, Dean, Patrick G., additional, Prieto, Mikel, additional, Cosio, Fernando G., additional, Kremers, Walter K., additional, Walker, Randall C., additional, Abraham, Roshini S., additional, and Stegall, Mark D., additional

Published
2010
Full Text
View/download PDF

45. Systemic Histoplasmosis

Author

Assi, Maha A., primary, Sandid, Mohamad S., additional, Baddour, Larry M., additional, Roberts, Glenn D., additional, and Walker, Randall C., additional

Published
2007
Full Text
View/download PDF

47. Differences between Early and Late Posttransplant Lymphoproliferative Disorders in Solid Organ Transplant Patients: Are They Two Different Diseases?

Author

Ghobrial, Irene M., primary, Habermann, Thomas M., additional, Macon, William R., additional, Ristow, Kay M., additional, Larson, Timothy S., additional, Walker, Randall C., additional, Ansell, Stephen M., additional, Gores, Gregory J., additional, Stegall, Mark D., additional, and McGregor, Christopher G., additional

Published
2005
Full Text
View/download PDF

48. Cardiac Xenotransplantation: Progress Toward the Clinic

Author

McGregor, Christopher G. A., primary, Teotia, Sumeet S., additional, Byrne, Guerard W., additional, Michaels, Marian G., additional, Risdahl, Jack M., additional, Schirmer, Johannes M., additional, Tazelaar, Henry D., additional, Walker, Randall C., additional, and Logan, John S., additional

Published
2004
Full Text
View/download PDF

49. Clinical Manifestations and Management of Left Ventricular Assist Device–Associated Infections.

Author

Nienaber, Juhsien Jodi C., Kusne, Shimon, Riaz, Talha, Walker, Randall C., Baddour, Larry M., Wright, Alan J., Park, Soon J., Vikram, Holenarasipur R., Keating, Michael R., Arabia, Francisco A., Lahr, Brian D., and Sohail, M. Rizwan

Subjects
HEART assist devices, INFECTION, HEART failure, ENDOCARDITIS, ANTI-infective agents, PATHOGENIC microorganisms
Abstract

We report the clinical manifestations and management of continuous-flow left ventricular assist device (LVAD) infections from a large multicenter cohort. On the basis of these observations, a management algorithm is derived to assist clinical decision making for LVAD infection.Background. Infection is a serious complication of left ventricular assist device (LVAD) therapy. Published data regarding LVAD-associated infections (LVADIs) are limited by single-center experiences and use of nonstandardized definitions.Methods. We retrospectively reviewed 247 patients who underwent continuous-flow LVAD implantation from January 2005 to December 2011 at Mayo Clinic campuses in Minnesota, Arizona, and Florida. LVADIs were defined using the International Society for Heart and Lung Transplantation criteria.Results. We identified 101 episodes of LVADI in 78 patients (32%) from this cohort. Mean age (± standard deviation [SD]) was 57±15 years. The majority (94%) underwent Heartmate II implantation, with 62% LVADs placed as destination therapy. The most common type of LVADIs were driveline infections (47%), followed by bloodstream infections (24% VAD related, and 22% non-VAD related). The most common causative pathogens included gram-positive cocci (45%), predominantly staphylococci, and nosocomial gram-negative bacilli (27%). Almost half (42%) of the patients were managed by chronic suppressive antimicrobial therapy. While 14% of the patients had intraoperative debridement, only 3 underwent complete LVAD removal. The average duration (±SD) of LVAD support was 1.5±1.0 years. At year 2 of follow-up, the cumulative incidence of all-cause mortality was estimated to be 43%.Conclusion. Clinical manifestations of LVADI vary on the basis of the type of infection and the causative pathogen. Mortality remained high despite combined medical and surgical intervention and chronic suppressive antimicrobial therapy. Based on clinical experiences, a management algorithm for LVADI is proposed to assist in the decision-making process. [ABSTRACT FROM AUTHOR]

Published
2013

50. PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION IN LIVER TRANSPLANTATION

Author

Badley, Andrew D., primary, Seaberg, Eric C., additional, Porayko, Michael K., additional, Wiesner, Russell H., additional, Keating, Michael R., additional, Wilhelm, Mark P., additional, Walker, Randall C., additional, Patel, Robin, additional, Marshall, William F., additional, DeBernardi, Michael, additional, Zetterman, Rowen, additional, Steers, Jeffrey L., additional, and Paya, Carlos V., additional

Published
1997
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results